AIMS: Delayed lipoprotein clearance is associated with atherosclerosis. This study examined whether chronic intermittent hypoxia (CIH), a hallmark of obstructive sleep apnoea (OSA), can lead to hyperlipidaemia by inhibiting clearance of triglyceride rich lipoproteins (TRLP). METHODS AND RESULTS: Male C57BL/6J mice on high-cholesterol diet were exposed to 4 weeks of CIH or chronic intermittent air (control). FIO(2) was decreased to 6.5% once per minute during the 12 h light phase in the CIH group. After the exposure, we measured fasting lipid profile. TRLP clearance was assessed by oral gavage of retinyl palmitate followed by serum retinyl esters (REs) measurements at 0, 1, 2, 4, 10, and 24 h. Activity of lipoprotein lipase (LpL), a key enzyme of lipoprotein clearance, and levels of angiopoietin-like protein 4 (Angptl4), a potent inhibitor of the LpL activity, were determined in the epididymal fat pads, skeletal muscles, and heart. Chronic intermittent hypoxia induced significant increases in levels of total cholesterol and triglycerides, which occurred in TRLP and LDL fractions (P< 0.05 for each comparison). Compared with control mice, animals exposed to CIH showed increases in REs throughout first 10 h after oral gavage of retinyl palmitate (P< 0.05), indicating that CIH inhibited TRLP clearance. CIH induced a >5-fold decrease in LpL activity (P< 0.01) and an 80% increase in Angptl4 mRNA and protein levels in the epididymal fat, but not in the skeletal muscle or heart. CONCLUSIONS: CIH decreases TRLP clearance and inhibits LpL activity in adipose tissue, which may contribute to atherogenesis observed in OSA.
AIMS: Delayed lipoprotein clearance is associated with atherosclerosis. This study examined whether chronic intermittent hypoxia (CIH), a hallmark of obstructive sleep apnoea (OSA), can lead to hyperlipidaemia by inhibiting clearance of triglyceride rich lipoproteins (TRLP). METHODS AND RESULTS: Male C57BL/6J mice on high-cholesterol diet were exposed to 4 weeks of CIH or chronic intermittent air (control). FIO(2) was decreased to 6.5% once per minute during the 12 h light phase in the CIH group. After the exposure, we measured fasting lipid profile. TRLP clearance was assessed by oral gavage of retinyl palmitate followed by serum retinyl esters (REs) measurements at 0, 1, 2, 4, 10, and 24 h. Activity of lipoprotein lipase (LpL), a key enzyme of lipoprotein clearance, and levels of angiopoietin-like protein 4 (Angptl4), a potent inhibitor of the LpL activity, were determined in the epididymal fat pads, skeletal muscles, and heart. Chronic intermittent hypoxia induced significant increases in levels of total cholesterol and triglycerides, which occurred in TRLP and LDL fractions (P< 0.05 for each comparison). Compared with control mice, animals exposed to CIH showed increases in REs throughout first 10 h after oral gavage of retinyl palmitate (P< 0.05), indicating that CIH inhibited TRLP clearance. CIH induced a >5-fold decrease in LpL activity (P< 0.01) and an 80% increase in Angptl4 mRNA and protein levels in the epididymal fat, but not in the skeletal muscle or heart. CONCLUSIONS:CIH decreases TRLP clearance and inhibits LpL activity in adipose tissue, which may contribute to atherogenesis observed in OSA.
Authors: Luciano F Drager; Luiz A Bortolotto; Cristiane Maki-Nunes; Ivani C Trombetta; Maria Janieire N N Alves; Raffael F Fraga; Carlos E Negrão; Eduardo M Krieger; Geraldo Lorenzi-Filho Journal: Atherosclerosis Date: 2009-08-19 Impact factor: 5.162
Authors: Michael M Weinstein; Liya Yin; Anne P Beigneux; Brandon S J Davies; Peter Gin; Kristine Estrada; Kristan Melford; Joseph R Bishop; Jeffrey D Esko; Geesje M Dallinga-Thie; Loren G Fong; André Bensadoun; Stephen G Young Journal: J Biol Chem Date: 2008-10-08 Impact factor: 5.157
Authors: Michael M Weinstein; Liya Yin; Yiping Tu; Xuping Wang; Xiaohui Wu; Lawrence W Castellani; Rosemary L Walzem; Aldons J Lusis; Loren G Fong; Anne P Beigneux; Stephen G Young Journal: Arterioscler Thromb Vasc Biol Date: 2009-10-08 Impact factor: 8.311
Authors: Vladimir Savransky; Jonathan Jun; Jianguo Li; Ashika Nanayakkara; Shannon Fonti; Ann B Moser; Kimberly E Steele; Michael A Schweitzer; Susheel P Patil; Sanjay Bhanot; Alan R Schwartz; Vsevolod Y Polotsky Journal: Circ Res Date: 2008-10-02 Impact factor: 17.367
Authors: Naresh M Punjabi; Brian S Caffo; James L Goodwin; Daniel J Gottlieb; Anne B Newman; George T O'Connor; David M Rapoport; Susan Redline; Helaine E Resnick; John A Robbins; Eyal Shahar; Mark L Unruh; Jonathan M Samet Journal: PLoS Med Date: 2009-08-18 Impact factor: 11.069
Authors: Luciano F Drager; Vsevolod Y Polotsky; Christopher P O'Donnell; Sergio L Cravo; Geraldo Lorenzi-Filho; Benedito H Machado Journal: Am J Physiol Heart Circ Physiol Date: 2015-07-31 Impact factor: 4.733
Authors: Luciano F Drager; Thauany M Tavoni; Vanessa M Silva; Raul D Santos; Rodrigo P Pedrosa; Luiz A Bortolotto; Carmen G Vinagre; Vsevolod Y Polotsky; Geraldo Lorenzi-Filho; Raul C Maranhao Journal: J Lipid Res Date: 2018-04-08 Impact factor: 5.922
Authors: Luciano F Drager; Luciano Drager; Vsevolod Y Polotsky; Luciano Polotsky Journal: Am J Respir Crit Care Med Date: 2011-08-01 Impact factor: 21.405
Authors: Jonathan C Jun; Mi-Kyung Shin; Qiaoling Yao; Shannon Bevans-Fonti; James Poole; Luciano F Drager; Vsevolod Y Polotsky Journal: Am J Physiol Endocrinol Metab Date: 2012-05-22 Impact factor: 4.310
Authors: Qiaoling Yao; Mi-Kyung Shin; Jonathan C Jun; Karen L Hernandez; Neil R Aggarwal; Jason R Mock; Jason Gay; Luciano F Drager; Vsevolod Y Polotsky Journal: J Lipid Res Date: 2013-02-05 Impact factor: 5.922
Authors: Luciano F Drager; Qiaoling Yao; Karen L Hernandez; Mi-Kyung Shin; Shannon Bevans-Fonti; Jason Gay; Thomas E Sussan; Jonathan C Jun; Allen C Myers; Gunilla Olivecrona; Alan R Schwartz; Nils Halberg; Philipp E Scherer; Gregg L Semenza; David R Powell; Vsevolod Y Polotsky Journal: Am J Respir Crit Care Med Date: 2013-07-15 Impact factor: 21.405